This trial will test whether direct oral anticoagulants are more effective than subcutaneous enoxaparin at preventing blood clots in patients undergoing autologous breast reconstruction.
1 Primary · 1 Secondary · Reporting Duration: 90-day events
Active Control
Experimental Treatment
106 Total Participants · 2 Treatment Groups
Primary Treatment: Apixaban 2.5 MG Oral Tablet · No Placebo Group · Phase 1 & 2
Age 18 - 89 · Female Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: